Suppression of thymic lymphomas and increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene

International Journal of Cancer

Volumn 111, Issue 6, 2004, Pages 819-828

  Tatemichi, Masayuki ^a,c   Tazawa, Hiroshi ^a   Masuda, Mitsuharu ^a,d   Saleem, Mohammad ^a,e   Wada, Sayori ^a   Donehower, Lawrence A ^b   Ohgaki, Hiroko ^a   Ohshima, Hiroshi ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TOHO UNIVERSITY   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bilateral effect; Double mutant mouse; INOS; Lymphomagenesis; Trp53

Indexed keywords

CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CARCINOGENESIS; CELL LINEAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENE DISRUPTION; GENE EXPRESSION; GENETIC DISORDER; GENETIC RECOMBINATION; HOMOZYGOSITY; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; LYMPHOMA; LYMPHOMAGENESIS; MOLECULAR MECHANICS; MOUSE; MOUSE STRAIN; NONHUMAN; NONTHYMIC LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; STRAIN DIFFERENCE; T LYMPHOCYTE; THYMUS LYMPHOMA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANIMALS; B-LYMPHOCYTES; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; INTERLEUKIN-10; LYMPHOMA; MICE; MUTATION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; THYMUS NEOPLASMS;

EID: 4143097181     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20350     Document Type: Article

References (51)

1. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003;417:3-11.
2. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002;12:311-20.
3. Salzman AL, Eaves-Pyles T, Linn SC, Denenberg AG, Szabo C. Bacterial induction of inducible nitric oxide synthase in cultured human intestinal epithelial cells. Gastroenterology 1998;114:93-102.
4. Laubach VE, Zhang CX, Russell SW, Murphy WJ, Sherman PA. Analysis of expression and promoter function of the human inducible nitric oxide synthase gene in DLD-1 cells and monkey hepatocytes. Biochim Biophys Acta 1997;1351:287-95.
5. Lin AW, Chang CC, McCormick CC. Molecular cloning and expression of an avian macrophage nitric-oxide synthase cDNA and the analysis of the genomic 5′-flanking region. J Biol Chem 1996;271:11911-9.
6. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-56.
7. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-11.
8. Calmels S, Hainaut P, Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 1997;57:3365-9.
9. Li CQ, Trudel LJ, Wogan GN. Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53. Proc Natl Acad Sci USA 2002;99:10364-9.
10. Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA 1998;95:8823-8.
11. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996;93:2442-7.
12. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT, Harris CC. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 1998;78:233-9.
13. Matsumoto M, Furihata M, Kurabayashi A, Araki K, Sasaguri S, Ohtsuki Y. Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma. Oncology 2003;64:90-6.
14. Brandao MM, Soares E, Salles TS, Saad ST. Expression of inducible nitric oxide synthase is increased in acute myeloid leukaemia. Acta Haematol 2001;106:95-9.
15. Aaltoma SH, Lipponen PK, Kosma VM. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001;21:3101-6.
16. Rajnakova A, Moochhala S, Goh PM, Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001;172:177-85.
17. Ward JM, Tadesse-Heath L, Perkins SN, Chattopadhyay SK, Hursting SD, Morse HC, III. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest 1999;79:3-14.
18. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr, Park SH, Thompson T, Ford RJ, Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995;14:16-22.
19. Tai XG, Toyo-oka K, Yamamoto N, Yashiro Y, Mu J, Hamaoka T, Fujiwara H. Expression of an inducible type of nitric oxide (NO) synthase in the thymus and involvement of NO in deletion of TCR-stimulated double-positive thymocytes. J Immunol 1997;158;4696-703.
20. Aiello S, Noris M, Piccinini G, Tomasoni S, Casiraghi F, Bonazzola S, Mister M, Sayegh MH, Remuzzi G. Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. J Immunol 2000;164:4649-58.
21. Gordon SA, Abou-Jaoude W, Hoffman RA, McCarthy SA, Kim YM, Zhou X, Zhang XR, Simmons RL, Chen Y, Schall L, Ford HR. Nitric oxide induces murine thymocyte apoptosis by oxidative injury and a p53-dependent mechanism. J Leukoc Biol 2001;70:87-95.
22. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
23. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995;92:10688-92.
24. Min/+ mice by inhibiting nitric oxide production. Cancer Res 2001;61:8357-60.
25. Ohgaki H, Fukuda M, Tohma Y, Huang H, Stoica G, Tatematsu M, Donehower LA. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol Carcinog 2000;28:97-101.
26. Tatemichi M, Nomura S, Ogura T, Sone H, Nagata H, Esumi H. Mutagenic activation of environmental carcinogens by microsomes of gastric mucosa with intestinal metaplasia. Cancer Res 1999;59:3893-8.
27. Virag L, Hasko G, Salzman AL, Szabo C. NADPH diaphorase histochemistry detects inducible nitric oxide synthetase activity in the thymus of naive and staphylococcal enterotoxin B-stimulated mice. J Histochem Cytochem 1998;46:787-91.
28. Ardavin C, Shortman K. Cell surface marker analysis of mouse thymic dendritic cells. Eur J Immunol 1992;22:859-62.
29. Hume DA, Robinson AP, MacPherson GG, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs. J Exp Med 1983;158:1522-36.
30. Blackwell BN, Bucci TJ, Hart RW, Turturro A. Longevity, body weight, and neoplasia in ad libitum-fed and diet-restricted C57BL6 mice fed NIH-31 open formula diet. Toxicol Pathol 1995;23:570-82.
31. Holan V, Krulova M, Zajicova A, Pindjakova J. Nitric oxide as a regulatory and effector molecule in the immune system. Mol Immunol 2002;38:989-95.
32. Dai WJ, Gottstein B. Nitric oxide-mediated immunosuppression following murine Echinococcus multilocularis infection. Immunology 1999;97:107-16.
33. Wu-Hsieh BA, Chen W, Lee HJ. Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Infect Immun 1998;66:5520-6.
34. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother 2001;55:543-7.
35. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002;99:10025-30.
36. Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 2002;62:932-40.
37. Ohkusu-Tsukada K, Tsukada T, Isobe K. Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 1999;163:1966-72.
38. Ajuebor MN, Virag L, Flower RJ, Perretti M, Szabo C. Role of inducible nitric oxide synthase in the regulation of neutrophil migration in zymosan-induced inflammation. Immunology 1998;95:625-30.
39. McCafferty DM, Sihota E, Muscara M, Wallace JL, Sharkey KA, Kubes P. Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol 2000;279:G90-9.
40. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binion DG, Musso A, West GA, Dobrea GM, McCormick TS, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-90.
41. Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 1995;154:4341-50.
42. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 1997;92:1-5.
43. Ameglio F, Cordiali FP, Solmone M, Bonifati C, Prignano G, Giglio A, Caprilli F, Gentili G, Capobianchi MR. Serum IL-10 levels in HIV-positive subjects: correlation with CDC stages. J Biol Regul Homeost Agents 1994;8:48-52.
44. Bansal AS, Bruce J, Hogan PG, Prichard P, Powell EE. Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-gamma is elevated in patients with hepatitis C infection. Clin Immunol Immunopathol 1997;84:139-44.
45. Carvalho EM, Bacellar O, Porto AF, Braga S, Galvao-Castro B, Neva F. Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors. J Acquir Immune Defic Syndr 2001;27:1-6.
46. Aydin F, Yilmaz M, Ozdemir F, Kavgaci H, Yavuz MN, Yavuz AA. Correlation of serum IL-2, IL-6 and IL-10 levels with international prognostic index in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 2002;25:570-2.
47. Mori N, Gill PS, Mougdil T, Murakami S, Eto S, Prager D. Interleukin-10 gene expression in adult T-cell leukemia. Blood 1996;88:1035-45.
48. Akamatsu S, Arai N, Hanaya T, Arai S, Tanimoto T, Fujii M, Kohno K, Micallef MJ, Ikeda M, Kurimoto M. Antitumor activity of interleukin-18 against the murine T-cell leukemia/lymphoma EL-4 in syngeneic mice. J Immunother 2002;25(Suppl 1):S28-34.
49. Sanchez-Bueno A, Verkhusha V, Tanaka Y, Takikawa O, Yoshida R. Interferon-gamma-dependent expression of inducible nitric oxide synthase, interleukin-12, and interferon-gamma-inducing factor in macrophages elicited by allografted tumor cells. Biochem Biophys Res Commun 1996;224:555-63.
50. Kim YM, Talanian RV, Li J, Billiar TR. Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). J Immunol 1998;161:4122-8.
51. Morse HC III, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Jaffe ES, Kogan SC, MacLennan IC, Pattengale PK, Ward JM. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002;100:246-58.